Cargando…
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
A high-throughput platform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing and antiviral screening. Here we present a high-throughput nanoluciferase severe respiratory syndrome coronavirus 2 (SARS-CoV-2-Nluc) that is genetically stable and replicates similarly to the...
Autores principales: | Xie, Xuping, Muruato, Antonio E., Zhang, Xianwen, Lokugamage, Kumari G., Fontes-Garfias, Camila R., Zou, Jing, Liu, Jianying, Ren, Ping, Balakrishnan, Mini, Cihlar, Tomas, Tseng, Chien-Te K., Makino, Shinji, Menachery, Vineet D., Bilello, John P., Shi, Pei-Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567097/ https://www.ncbi.nlm.nih.gov/pubmed/33060595 http://dx.doi.org/10.1038/s41467-020-19055-7 |
Ejemplares similares
-
Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
por: Xie, Xuping, et al.
Publicado: (2021) -
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility
por: Shi, Pei-Yong, et al.
Publicado: (2020) -
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility
por: Plante, Jessica A., et al.
Publicado: (2020) -
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
por: Muruato, Antonio E., et al.
Publicado: (2020) -
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
por: Muruato, Antonio E., et al.
Publicado: (2020)